16578744517_ed4293d3e7_z

Patient dies after receiving faecal transplant

pharmafile | June 17, 2019 | News story | Sales and Marketing Adverse Event, E.Coli. AMR, FDA, faecal transplant, pharma 

A person has died after experiencing an adverse event related to a faecal transplant.

The FDA has warned that two immunocompromised patients developed invasive infections caused by multi drug resistant bacteria, after receiving a faecal transplant.

The patients were infected with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E.coli) after receiving faecal microbiota for transplantation (FMT) from the same donor.

Advertisement

The donor stool and resulting FMT used in these two individuals were not tested for ESBL-producing gram-negative organisms prior to use.

Both patients then developed antibiotic resistant E.Coli infections. One of the patients subsequently died.

FMT is an experimental treatment Clostridium difficile, a bacterial infection which causes severe diarrhoea.

“While we support this area of scientific discovery, it’s important to note that FMT does not come without risk,” said Dr Peter Marks, director of FDA’s Center for Biologics Evaluation and Research.

“We’ve become aware of infections with multi-drug resistant organisms after patients received investigational FMT, including one patient death. We therefore want to alert all health care professionals who administer FMT about this potential serious risk so they can inform their patients.”

Louis Goss

Related Content

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631_1

Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation

Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content